Sobi® (STO: SOBI), today announced a research collaboration involving a new Phase 2a clinical trial for Gamifant® (emapalumab) for the potential treatment of interferon-gamma (IFNγ)-driven sepsis (IDS ...
Sobi® (STO: SOBI), today announced a research collaboration involving a new Phase 2a clinical trial for Gamifant® (emapalumab) for the potential treatment of interferon-gamma (IFN?)-driven sepsis (IDS ...
Pioneering the World's 1st Dark Matter Cancer Immunotherapy UbiVac's DPV-001 is the World's 1st Dark Matter Cancer Immunotherapy in the Cli ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback